To evaluate the effect of FEV1 (% of predicted) at the time of diagnosis on survival and performance status for patients with NSCLC.
Retrospective analysis of patients with NSCLC referred to our pulmonary function test laboratory between January 2001 and November 2001. Clinical characteristics, smoking history, comorbidities, survival, pulmonary function tests, and performance status (ZUBROD) at baseline, 6 months and 1 year were reviewed.
We studied 206 patients (M=120;F=86) with NSCLC. Mean age was 64.7±10.1 yrs. Fourty-five percent were smokers, 48% were former smokers, and 7% were nonsmokers. Average predicted percent FEV1=70.3%±19.6% (range 25%-123%). Smokers and former smokers averaged 52.4±30 pack-yr. Sixty-three percent of patients had at least one type of comorbidity; DM 15 (7%), HTN 66 (32%), CAD 47(23%). Also 59 (29%) patients had other type of malignancies. The histologic types were; Adenocarcinoma 87(42%), squamous 72(35%), large cell 43(21%), and BAC 4(2%). The stages of patients were IA:28 (14%), IB:27(13%), IIA:8(4%), IIB:31(15%), IIIA:48(23%), IIIB:39(19%) and IV:25(13%). When corrected for tumor stage, comorbidities, and age there was no significant association between initial FEV1% and patients’ survival and change of their performance status.
Pulmonary dysfunction measured by FEV1 % of predicted at the time of diagnosis did not independently affect survival or change in performance status for patients with NSCLC.
Degree of pulmonary dysfunction measured by FEV1 is important for selection and outcome of surgically treated patients, but is not a determinant factor of performance and survival for patients with NSCLC overall.
Sevin Baser, None.